HIV 1 SEQUENCE DIVERSITY AND PEDIATRIC AIDS
HIV 1 SEQUENCE DIVERSITY AND PEDIATRIC AIDS
批准号:
2889282
负责人:
RAPHAEL Paul VISCIDI
金额:
$37.21万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1997
资助国家:
美国
项目状态:
已结题
起止时间:
1997-04-01 至 2001-03-31
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (adapted from the Abstract): The importance of genetic
variation of HIV-1 for the pathogenesis of AIDS is unclear. The Principal
Investigator notes that a persistent viral infection, a high viral load, and
an error-prone replication mechanism provide ideal conditions for
evolutionary forces to shape the virus-host interaction during the course of
infection; he speculates that this process may have importance for viral
pathogenesis either through the emergence of strains capable of occupying
new ecological niches, such as different host cell types, or through the
generation of a population of viruses whose antigenic diversity overwhelms
the capacity of the host's immune system to contain them. The Investigator
and his associates have completed recently a study aimed at characterizing
the in vivo evolution of plasma HIV-1 env C2V3 sequences in relation to
disease progression in HIV-l infected infants. Six infants were followed
with sampling at approximately six-month intervals for two years. Two
progressed to AIDS within this time frame. The results from this study
indicate that infants who developed AIDS had an increased rate of nucleotide
substitution and showed a greater overall genetic diversity. Infants with
AIDS also showed sequentially dominant lineages, suggesting a process of
sequential replacement of variants, perhaps as a result of periodic escape
from the immune response or due to increasing tropism for a productive host
cell type. Phylogenetic analysis of deduced amino acid sequences showed a
clustering of V3 loop sequences detected at later time points from the two
infants with AIDS. These V3 loop sequences shared four amino acids in
positions shown to be genetic determinants of T-cell line tropism. The
evolutionary pattern suggests that viruses from these infants with AIDS have
acquired independently, through what appears to be an example of convergent
evolution, a similar and possibly more virulent phenotype. The aims of the
proposed research are to test the generality of these findings. One hundred
infants will be followed at three-month intervals for two years. The
Investigator proposes to sample 50 sequences from reverse transcribed viral
RNA at each time interval for each patient. However, by using heteroduplex
analysis, he will need to sequence only a fraction of these sequences. The
Investigator proposes to collect nucleotide sequence data and data for four
clinical phenotypes: (1) viral load, (2) CD4+ T-cell count, (3) clinical
classification, and (4) time. The data will be analyzed within a
phylogenetic framework using the intraspecific cladogram estimation
procedure of Templeton, which was developed for reconstruction of
within-species phylogenies and allows for a nested statistical design to
test hypotheses of association. The hypotheses to be tested fall into two
categories: (1) genetic diversity associated with disease progression; and
(2) association of genetic diversity with clinical phenotypes. In the first
category the researchers will ask whether infants who rapidly progress to
AIDS as compared to slow progressors have an increased rate of nucleotide
substitution, a greater proportion of nonsynonymous to synonymous nucleotide
substitutions, and greater HIV-l nucleotide diversity, and whether the
former infants show sequentially dominant lineages and convergent or
divergent motifs in the V3 loop. In the second category they will ask
whether an association exists between genetic diversity and viral load, CD4+
T cell count, clinical classification or time and, if an association is
found, whether the genetic avenues to the genotype related to the change in
phenotype are independent or convergent.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Virus-Like Particle Vaccine for SARS-CoV
-
批准号:7035180
-
项目类别:
-
资助金额:$38.94万
-
财政年份:2006
-
负责人:RAPHAEL Paul VISCIDI
-
依托单位:
Virus-Like Particle Vaccine for SARS-CoV
-
批准号:7218604
-
项目类别:
-
资助金额:$39.78万
-
财政年份:2006
-
负责人:RAPHAEL Paul VISCIDI
-
依托单位:
Virus-Like Particle Vaccine for SARS-CoV
-
批准号:7596920
-
项目类别:
-
资助金额:$39.05万
-
财政年份:2006
-
负责人:RAPHAEL Paul VISCIDI
-
依托单位:
Virus-Like Particle Vaccine for SARS-CoV
-
批准号:7795079
-
项目类别:
-
资助金额:$38.66万
-
财政年份:2006
-
负责人:RAPHAEL Paul VISCIDI
-
依托单位:
Virus-Like Particle Vaccine for SARS-CoV
-
批准号:7388873
-
项目类别:
-
资助金额:$39.05万
-
财政年份:2006
-
负责人:RAPHAEL Paul VISCIDI
-
依托单位:
Molecular Epidemiology of N. gonorrhoeae
-
批准号:6859397
-
项目类别:
-
资助金额:$54.19万
-
财政年份:2002
-
负责人:RAPHAEL Paul VISCIDI
-
依托单位:
Molecular Epidemiology of N. gonorrhoeae
-
批准号:6624151
-
项目类别:
-
资助金额:$51.08万
-
财政年份:2002
-
负责人:RAPHAEL Paul VISCIDI
-
依托单位:
Molecular Epidemiology of N. gonorrhoeae
-
批准号:6472573
-
项目类别:
-
资助金额:$51.18万
-
财政年份:2002
-
负责人:RAPHAEL Paul VISCIDI
-
依托单位:
Molecular Epidemiology of N. gonorrhoeae
-
批准号:6710045
-
项目类别:
-
资助金额:$52.61万
-
财政年份:2002
-
负责人:RAPHAEL Paul VISCIDI
-
依托单位:
Molecular Epidemiology of N. gonorrhoeae
-
批准号:7021462
-
项目类别:
-
资助金额:$54.51万
-
财政年份:2002
-
负责人:RAPHAEL Paul VISCIDI
-
依托单位:
HUMORAL IMMUNE RESPONSE TO NATURAL CHLAMYDIAL INFECTION
-
批准号:6099666
-
项目类别:
-
资助金额:$6.38万
-
财政年份:1998
-
负责人:RAPHAEL Paul VISCIDI
-
依托单位:
ANTIBODIES TO HPV CAPSID PROTEINS AS IMMUNITY CORRELATES
-
批准号:6170865
-
项目类别:
-
资助金额:$31.72万
-
财政年份:1998
-
负责人:RAPHAEL Paul VISCIDI
-
依托单位:
ANTIBODIES TO HPV CAPSID PROTEINS AS IMMUNITY CORRELATES
-
批准号:6373722
-
项目类别:
-
资助金额:$32.79万
-
财政年份:1998
-
负责人:RAPHAEL Paul VISCIDI
-
依托单位:
ANTIBODIES TO HPV CAPSID PROTEINS AS IMMUNITY CORRELATES
-
批准号:2441625
-
项目类别:
-
资助金额:$32.03万
-
财政年份:1998
-
负责人:RAPHAEL Paul VISCIDI
-
依托单位:
ANTIBODIES TO HPV CAPSID PROTEINS AS IMMUNITY CORRELATES
-
批准号:2887619
-
项目类别:
-
资助金额:$33.27万
-
财政年份:1998
-
负责人:RAPHAEL Paul VISCIDI
-
依托单位:
HIV 1 SEQUENCE DIVERSITY AND PEDIATRIC AIDS
-
批准号:6181816
-
项目类别:
-
资助金额:$38.41万
-
财政年份:1997
-
负责人:RAPHAEL Paul VISCIDI
-
依托单位:
HIV 1 SEQUENCE DIVERSITY AND PEDIATRIC AIDS
-
批准号:2332304
-
项目类别:
-
资助金额:$47.14万
-
财政年份:1997
-
负责人:RAPHAEL Paul VISCIDI
-
依托单位:
HIV 1 SEQUENCE DIVERSITY AND PEDIATRIC AIDS
-
批准号:2673998
-
项目类别:
-
资助金额:$44.3万
-
财政年份:1997
-
负责人:RAPHAEL Paul VISCIDI
-
依托单位:
HUMORAL IMMUNE RESPONSE TO NATURAL CHLAMYDIAL INFECTION
-
批准号:6235138
-
项目类别:
-
资助金额:$15.65万
-
财政年份:1997
-
负责人:RAPHAEL Paul VISCIDI
-
依托单位:
IMMUNOLOGICAL MARKERS OF HPV INFECTION & RELATED CANCER
-
批准号:2097361
-
项目类别:
-
资助金额:$23.07万
-
财政年份:1992
-
负责人:RAPHAEL Paul VISCIDI
-
依托单位:
海外基金